Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | NOS1 | P29475 | 5/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14487466 | 0.79 | METAP2 (0.56) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL22499161 | 0.76 | TDO2 (0.61) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL31299391 | 0.76 | METAP2 (0.53) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL2289231 | 0.76 | IDO1 (0.61) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL29981288 | 0.76 | METAP2 (0.53) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL2003535 | 0.76 | METAP2 (0.53) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL17739410 | 0.76 | METAP2 (0.53) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL14737953 | 0.76 | METAP2 (0.53) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL16682088 | 0.76 | METAP2 (0.53) | METAP2NOS1DYRK1AIDO1TDO2 | |
| SCHEMBL24355254 | 0.72 | METAP2 (0.56) | METAP2NOS1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102372675-B | 6-chlorine-4-iodine indazole, preparation method and application thereof | WANG NA | 2013-12-18 | — | — | CN | claimed |
| CN-102372675-A | 6-chlorine-4-iodine indazole, preparation method and application thereof | SHENZHEN INOVA MEDICAL TECHNOLOGY DEV CO LTD | 2012-03-14 | — | — | CN | claimed |
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4076443-B1 | SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUND AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| WO-2010125082-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | METAP2 50/4885NOS1 1520/4885DYRK1A 3864/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | METAP2 3652/4885NOS1 3887/4885DYRK1A 1348/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | METAP2 2602/4885NOS1 2849/4885DYRK1A 1594/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | METAP2 1631/4885NOS1 4845/4885DYRK1A 2227/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | METAP2 203/4885NOS1 550/4885DYRK1A 3860/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | METAP2 2602/4885NOS1 2849/4885DYRK1A 1594/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | METAP2 1631/4885NOS1 4845/4885DYRK1A 2227/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | METAP2 3606/4885NOS1 4649/4885DYRK1A 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.